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Abstract
Portal vein tumor thrombosis (PVTT) is a common paraneoplastic condition in advanced 
primary hepatocellular carcinoma or hepatobiliary tract malignancies. Tumors with PVTT are 
frequently associated with adverse and aggressive features such as intrahepatic tumor dis-
semination, early treatment failure, or deterioration of hepatic function. Therefore, the treat-
ment outcomes for PVTT in historical series are often dismal and discouraging. More recently, 
beneficial effects and excellent outcomes of external beam radiation therapy (EBRT) for treat-
ing this disease have been reported, and the use of EBRT is becoming more common because 
of the non-invasive nature of RT and rapid advances in RT technology. We hope to be able to 
cure this devastating condition in the near future with more advanced and efficacious disease 
management strategies. The current status and clinical trial results for EBRT as a promising 
treatment option for managing PVTT will be discussed here. Copyright © 2014 S. Karger AG, Basel
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IntroductionHepatocellular carcinoma (HCC) is one of the most common neoplasms worldwide, and this is also the case in Asia [1, 2]. Although HCC survival rates have been steadily increasing thanks to innovative diagnostic and therapeutic options, the prognosis for patients with this disease remains dismal and discouraging [3–7].The lifetime cumulative incidence of portal vein thrombosis (PVT) was reported to be 
approximately 1% in a population-based study, but this figure increases to 30–40% when combined with other cancerous conditions such as primary HCC or hepatobiliary tract ma-lignancies [8]. Portal vein tumor thrombosis (PVTT) is now a more commonly and widely 
used term for PVT associated with those malignancies. The clinical significance of PVTT in 
HCC patients has been well documented in a number of previous publications. Briefly, the multicentric nature of HCC is commonly associated with PVTT, and, conversely, PVTT or great vessel invasion in HCC also promotes intrahepatic tumor spreading, leading to disease progression, early treatment failure, or deterioration of liver function [9–11]. In addition, the 
existence of PVTT or intrahepatic vascular invasion in HCC is reflected in the national cancer staging system and implies a more advanced and intractable tumor condition [12, 13].Historically, selected patients with non-bulky, localized PVTT with primary HCC were 
treated with surgical resection, transarterial chemoembolization (TACE) [14], or intra-arte-
rial chemo-infusion [15] but the outcomes and efficacies were unsatisfactory [16–18].
More recently, beneficial responses and excellent outcomes after external beam radia-
tion therapy (EBRT) in HCC patients have been reported, and EBRT is now officially rec-ommended as one of the therapeutic options for inoperable liver cancer by the National Comprehensive Cancer Network guidelines [19]. In addition, promising results after EBRT have been noted, particularly in PVTT management. Although the effectiveness of EBRT has been limited by low whole-liver radiation tolerance and the low tolerance of adjacent critical structures, the recent development of modern EBRT technologies, including three-dimen-sional conformal RT (3D-CRT), intensity-modulated RT (IMRT), image-guided RT (IGRT), particle therapies, and improved understanding of the partial volume radiation tolerance of the liver and surrounding organs, has allowed higher doses of EBRT to be delivered with 
higher precision and without significant increases in treatment-related toxicities [4, 6, 20–23]. With these technical improvements, PVTT may become potentially curable by EBRT.In this review, we discuss the current status and recent results for EBRT as a promising method for PVTT management and consider future strategies to further enhance the thera-
peutic efficacy of EBRT with respect to PVTT, a commonly encountered difficulty in patients with advanced HCC.
Rationale of PVTT Treatment and an Overview of Non-Radiation-Based  
ApproachesAdvanced HCC frequently invades the large intrahepatic vessels, including the main PV branches and the hepatic veins, or the inferior vena cava (IVC). PVTT causes partial or com-plete obstruction of major PV branches, leading to a number of serious complications such as portal hypertension, esophageal variceal bleeding or rupture, intractable ascites, ischemic 
liver injury, and sudden cardiac death [24].
The median overall survival (OS) of HCC patients with PVTT is reported to be 2–4 
months if no further treatment is given [24], which is a very disappointing result. An early report by Mitsunobu et al. [25] showed a strong statistical correlation between intrahepatic metastases and the frequency of vascular invasion. Using radiopaque material injected di-
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rectly into the tumors, they observed flow of the injected material only into the PV in unre-
sectable lesions. These findings demonstrated the possible role of great vessel invasion in the process of pathogenic mechanisms of intrahepatic dissemination or multifocal recurrence in HCC patients.PVTT in HCC patients has been managed by various treatment options, including local 
therapy or combined systemic treatment [16–18, 26–28]. In selected patients with good he-patic reserves and non-extensive, localized HCC with PVTT, curable surgical resection can be attempted. However, the majority of patients present with multicentric, multinodular, or disseminated disease states that limit curable surgical approaches. Historically, TACE was regarded as generally unsuitable for HCC with PVTT because of the risk of severe ischemic liver injury. However, recent trials have revealed that TACE can be successfully performed in eligible patients who have well-developed collateral circulation around the main portal 
branches. Intra-arterial chemo-infusion with 5-fluorouracil (5-FU) and/or cisplatin (CDDP) or immunotherapy has been attempted and yielded moderate tumor response rates. In addi-
tion, intensified chemotherapy delivery methods via TACE have been recently developed [29].Representative historical results of non-radiation approaches for treating HCC with PVTT are described in table 1. Surgery as a local therapeutic approach for PVTT was reported in 
several previous studies [17, 26, 27, 30, 31]. Liu et al. [27] stated that hepatectomy and throm-
bectomy significantly prolonged OS and recurrence-free survival compared with the group receiving only chemotherapy in patients with HCC and PVTT. The incidence rates of 1-year 
recurrence in surgery and chemotherapy groups were 27.7 and 70%, respectively. They con-cluded that hepatectomy and thrombectomy employing total hepatic vascular exclusion was a 
viable surgical option and resulted in a better quality of life than chemotherapy alone. Lin et 
al. [26] and Chen et al. [30] also supported the aggressive approach of surgical management and demonstrated successful outcomes in the treatment of PVTT. In contrast, Kondo et al. [17] 
reported that hepatic resection as a first-choice treatment should be carefully considered in patients with main branch PVTT because no patient with PVTT of the main branch survived 
for more than 400 days after surgery; surgery in patients with PVTT in the main branch more frequently resulted in severe compli cations compared with surgery in patients with PVTT in sub-branches.TACE alone, combined therapy consisting of intraarterial chemo-infusion and systemic immunotherapy, and percutaneous ethanol injection for cure of PVTT were also investigated 
[16, 18, 32]. Luo et al. [18] performed a prospective comparative study to elucidate the ef-
ficacy of TACE compared with conservative treatment alone. A significantly better survival 
was observed in the TACE group with a 1-year OS rate of 30.9% compared with 3.8% in the conservative treatment group. TACE consistently and favorably affected survival outcomes in subgroups with segmental and major PVTT.Dramatic responses of PVTT to systemic targeted agents have also been reported. Novi 
et al. [33] and Basso et al. [34] reported a complete response (CR) and recanalization of the PV after treatment with sorafenib and sunitinib, respectively. Yau et al. [28] emphasized the 
beneficial effect of sorafenib used as a single agent in PVTT control with an 18.2% partial 
response (PR) rate and a 13.6% stable disease (SD) rate in their phase 2 open-label study of 
sorafenib in an Asian population. In that study, there were no significant differences between 
patients with and without PVTT in terms of benefit, OS, and toxicity of sorafenib.
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Role of Radiation Therapy: Clinical Outcomes of 3D-CRT for Treatment of PVTT 
with or without an Encompassing Primary Liver TumorNumerous studies of EBRT for treatment of HCC with PVTT have resulted in good re-
sponses and promising treatment outcomes [4, 11, 21, 35–37]. The rationale of targeting PVTT in HCC patients using EBRT is the restoration of PV patency and inhibition of further 
tumor growth or spread into the intrahepatic or intravascular areas. Further treatments (e.g., TACE) may be considered after or before restoring PV patency. Additionally, recent advanc-es in IGRT and IMRT techniques contributed to high-dose and highly focused EBRT delivery 
while simultaneously minimizing the risk of severe toxicities [4, 38]. These approaches have made PVTT in HCC patients a potentially curable disease.Several previous publications have reported outcomes of PVTT treated with or without 
3D-CRT [39–44]. Table 2 summarizes the clinical results after EBRT for treatment of PVTT only with or without other treatments. Use of 3D-CRT as a sole therapeutic option for target-
ing PVTT was rarely reported, suggesting an inadequate beneficial effect of EBRT alone for 
that condition. In a report by Nakagawa et al. [40], 52 patients received PV invasion-targeting 
treatment using a median 57 Gy of 3D-CRT in a daily dose of 2 Gy; CR/PR was achieved in 26 
(50%) patients and the 3-year OS rate was 15.2%. Multivariate analysis indicated that signifi-cant prognostic factors for OS were the number of tumor foci and TACE after EBRT. Tradition-ally, TACE was used either before or after EBRT to more effectively eradicate and sterilize 
residual lesions. Response rates for EBRT with TACE ranged from 45–60%, and median OS 
rates ranged from 8–10 months. In a more recent study by Zhang et al. [44], the efficacy of percutaneous transhepatic PV stenting and TACE with or without 3D-CRT was evaluated. The 
objective response rate was 35.6% (CR+PR), and more durable stent patency was observed when treatment was combined with 3D-CRT. The median OS in the group with combined PV 
stenting and 3D-CRT was 16.5 months, a promising result. In another report by Katamura et 
al. [39], intra-arterial 5-FU with interferon-α was combined with 3D-CRT, and the efficacy of 
Table 2. Clinical results after radiation therapy to PVTT onlyAuthors  [reference] No. of patients Treatment Total RT dose (range)/ fractional dose (in Gy) Response rate (CR+PR,%) Median survival (months)Tazawa et al.  
[41]
24 EBRT+TACE 50 (N/A)/2 50 (CR 16.7) CR/PR (9.7),  
NR/PD (3.8)Yamada et al.  
[42]
19 3D-CRT+(TACE for  liver tumor) Mean 57 (46–60)/2 57.9 (CR 0) 7Nakazawa et al.  
[24]
52 3D-CRT 57 (39–60) 50 (CR 15.4) 3-year survival 15.2%
Zeng et al.  
[43]
44 RT+TACE 50 (36–60)/2 45.5 (CR 34.1) RT 8,  
non-RT 4Katamura et al.  [39] 32 iA 5-FU/IFN+3D-CRT/ iA 5-FU/IFN 39 (30–45)/3 RT 75,  non-RT 25 RT 7.5,  non-RT 7.9
Zhang et al.  
[44]
45 PV stenting+TACE 
+3D-CRT/PV stenting+TACE 40 (30–60)/2 35.6 (CR 0) RT 16.5,  non-RT 4.8
RT = radiation therapy; NR = no response; PD = progressive disease; iA = intra-arterial; IFN = interferon.
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this combined treatment was compared with a non-RT group (matched controls). The objec-tive response rate of PVTT was higher in the RT group, i.e., 75% in the RT group and 25% 
in the non-RT group. However, median OS was not significantly different between the two study arms (7.5 months in the RT group vs. 7.9 months in the non-RT group).Clinical results of previous studies targeting PVTT and primary liver tumors are sum-marized in table 3. Han et al. [35] performed a clinical pilot study of localized concurrent 
chemoradiation with 5-FU followed by hepatic arterial chemo-infusion with 5-FU and CDDP for locally advanced HCC with PVTT. The 1 month objective response rate in an intention-to-
treat analysis was 45%, with a median survival time of 13.1 months. Patients who respond-
ed to localized chemoradiation therapy showed significantly better survival outcomes (p = 
0.033) than non-responders. Among 40 recruited patients, 12 patients (30%) had intrahe-patic tumor recurrence, the majority of which developed recurrence in an area outside the 
RT field. Kim et al. [21] reported a response rate for PVTT treatment of 45.8% with 6.8% CR 
using a 30–54 Gy 3D-CRT dose given in 2–3 Gy fractions. The response rate was statistically 
higher (54.6%) for those treated with a dose greater than or equal to the biologically equiva-
lent dose (BED) of 58 Gy in an α/β ratio of 10 compared with those treated with less than 58 
Gy (20%). The median OS in responders and non-responders was 10.7 and 5.3 months, re-
spectively (p = 0.05). Yu et al. [37] suggested a prognostic model based on the retrospective 
review of 281 HCC patients with PVTT. In their report, a total RT dose of 30–54 Gy was given 
in 1.8–4.5 Gy daily fractional doses. PVTT and main intrahepatic masses completely disap-
peared in 10 (3.6%) patients and PR was achieved in 141 (50.2%) patients. In a multivariate analysis, poor Eastern Cooperative Oncology Group (ECOG) performance status, unfavorable Child-Pugh class, multiple tumors, main branch PVTT, complete portal vein occlusion, lymph 
node metastasis, and large primary tumor size were significantly associated with OS. Prog-nostic index scores based on these factors correlated well with OS. In a recent large retro-
Table 3. Clinical results after RT to both the PVTT and primary liver tumorAuthors  [reference] No. of  patients Treatment Total RT dose (range)/fractional dose (in Gy) Response rate (CR+PR,%) Median survival (months)Ishikura  
et al. [10]
20 EBRT+TACE 50 (N/A)/2 50 (CR 0) 5.3
Kim et al.  [21] 59 3D-CRT N/A (30–54)/2–3 45.8 (CR 6.8) Responders 10.7, non-responders 5.3Kim et al.  
[36]
41 3D-CRT 54 (44–54)/2–3 39 (CR 9.7) Responders 20.1, non-responders 7.2You et al.  
[48]
49 3D-CRT+TACE N/A (40–45)/1.8–2 48 (CR 0) TACE 13, TACE+RT 13.5Toya et al.  
[46]
38 3D-CRT 40 (17.5–50.4)/1.8–4 44.7 (CR 15.8) 9.6
Yu et al.  [37] 281 3D-CRT+TACE N/A (30–54)/1.8–4.5 53.8 (CR 3.6) Responders 22, non-responders 5Yoon et al.  [11] 412 3D-CRT+TACE 40 (21–60)/2–5 27.9 (CR 3.6) 10.6
24
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spective study performed by Yoon et al. [11], outcomes of 412 patients treated with TACE and 3D-CRT were analyzed. Intrahepatic primary HCC was managed by TACE before or after EBRT 
with a median total EBRT dose of 40 Gy (range, 21–60 Gy) delivered in 2–5 Gy fractions. The target volume was organized according to the primary tumor size. When the tumor burden was small or TACE was incomplete, the gross tumor volume (GTV) included the entire HCC 
and PVTT. On the other hand, with large, infiltrative HCC with PVTT a 2- to 3-cm margin into the contiguous HCC was included in the generation of the GTV. CR and PR rates were found to 
be 3.6% and 24.3%, respectively. Grade 3–4 hepatic toxicity during EBRT or within 3 months 
after completion of EBRT was 10%. Overall, Yoon et al. concluded that TACE and EBRT combi-nation treatment was a safe and effective option for PVTT management in patients with HCC.The majority of previous trials evaluated response rates and survival outcomes. However, different methods of response evaluation and the heterogeneous compositions of additional 
treatments among different studies made it difficult to accurately assess treatment responses. Moreover, the optimal timing of response evaluation and accurate determination of the radio-graphic response are still debatable. Effects on the OS according to PVTT response are more 
clear, with a modest benefit in OS in PVTT responders. In terms of RT volume, encompassing both the primary tumor and the PVTT seems to be reasonable approach within allowable bounds of EBRT dose limits.
Dose-Response of PVTT to Radiation TherapyAlthough the response of PVTT to the chosen treatment was one of the main end-points in the majority of studies, the dose-response relationship to 3D-CRT was not routinely evalu-ated. The reason for this is most likely the common employment of other combination thera-pies (e.g., TACE) or a relatively homogeneous EBRT dose administration in patient cohorts within studies. The association between the total delivered EBRT dose and the patient’s per-formance status or other confounding factors must be carefully evaluated.Several studies evaluated dose-response with 3D-CRT alone for the treatment of PVTT 
[21, 36, 45, 46]. Because the fractional dose was different among studies, the BED equation 
was most frequently utilized using an α/β ratio of 10 to estimate dose-response. Toya et al. 
[46] reported that the response rate and OS was substantially higher in patients who received a BED10 ≥58 Gy than in those who received a BED10 <58 Gy. The size of the tumor thrombus 
was also a significant factor when evaluating the treatment of PVTT. In a publication by Kim et 
al. [36], no objective response was observed in patients receiving a BED10 <64 Gy, but an ob-
jective response rate of 50% was achieved in patients receiving a BED10 ≥64 Gy. Although the 
BED was not significantly correlated with OS, a trend towards longer survival was observed in patients receiving a BED10 ≥64 Gy (11.2 months vs. 6.8 months, p = 0.140). Kim et al. [21] also observed a dose-dependent response for the treatment of PVTT. The objective response 
of PVTT was 20% with a BED10 <58 Gy and 54.6% with a BED10 ≥58 Gy. Responders (CR+PR) 
lived longer with a median OS of 10.7 months compared with non-responders with a median 
OS of 5.3 months (p = 0.05). More recently, Rim et al. [45] reported successful and promising outcomes with high-dose 3D-CRT for PVTT. The median BED10 was 72.2 Gy and the objective 
response rate was 62.3%.
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Efficacy and Toxicity of PVTT Treatment with Radiation TherapyHistorical data have shown that PVTT without further treatment results in poor sur-
vival outcomes, with a median OS of only 2–4 months [24]. Direct comparison of outcomes between a cohort of untreated and treated patients has never been performed, because it seems rational to appropriately manage this debilitating condition at the earliest possibly 
opportunity. The objective estimation of PVTT treatment efficacy is complicated, and the majority of trials evaluated objective response rates using changes in tumor diameter and related survival outcomes as an assessment of treatment response.The response of PVTT to 3D-CRT alone was separately evaluated in a publication by 
Kim et al. [36]. The objective response rate of PVTT treatment was 39% with a 9.7% CR rate. 
With respect to HCC, the primary tumor response rate was 54.3% with a 5.7% CR rate. Kim 
et al. [21] also reported an objective PVTT treatment response rate to 3D-CRT of 45.8% with 
a 6.8% CR rate. Hou et al. [47] explored the relationship between PVTT location and EBRT response. Patients with IVC thrombus had a better response rate and longer survival than those with PVTT.Combination therapy including 3D-CRT and TACE with or without other therapies is commonly utilized for the treatment of PVTT with the goal of more effective disease oblit-
eration [11, 35, 37, 43, 48]. Han et al. [35] announced that the response rate was 45%, with 
no patients achieving CR, after localized chemoradiation only. However, 10% of the patient 
cohort achieved CR after additional hepatic arterial infusion chemotherapy. Zeng et al. [43] 
reported an objective response rate of 45.5% for PVTT treatment by 3D-CRT plus TACE. Yu 
et al. [37] reported a response rate of 53.8% with a CR of 3.6% in their study. You et al. 
[48] reported a 3-month objective response rate of 48% with 3D-CRT plus TACE compared 
with 18.2% with 3D-CRT alone. Yoon et al. [11] stated that a 39.6% response rate could be 
achieved with a CR of 6.6% with 3D-CRT plus TACE. They also reported that the progression-
free rate of patients with PVTT was a promising 85.6%. Representative images of CR of PVTT 
after concurrent chemoradiation are shown in figure 1.The integration of EBRT and TACE evidently appeared to increase the response rate and 
OS in patients with PVTT compared with EBRT alone or TACE alone. Zeng et al. [43] reported 
a CR of 34.1% when EBRT and TACE were combined, and patients achieved significantly enhanced survival durations. Interestingly, they reported that patients with untreated IVC 
tumor thrombi survived a median of 2 months, but EBRT served as a significant protective 
factor for prolonging OS duration to a median 22 months. You et al. [48] similarly described 
enhanced response rates of up to 48% with the addition of EBRT. However, the effect of com-bined therapy using EBRT and TACE on OS was unclear in their report.
Treatment-related toxicities were reported in most studies, but specific toxic effects 
of PVTT treatment were seldom found, and most cases were of non-specific liver toxicities 
or were associated with RT-related toxicity. Non-specific gastrointestinal side effects such as anorexia, nausea, or vomiting were the most commonly reported. However, these were well managed with proper medications or temporary rest from EBRT and were not usually 
a treatment-limiting factor. Although endoscopic findings revealed frequent gastroduodenal mucosal changes after EBRT, high-grade gastric or duodenal ulcer bleeding or perforation 
was rare, with a frequency of less than 1% [42, 49]. However, a causal relationship between 
toxicity and EBRT dose was not demonstrated. Yamada et al. [42] studied the use of an an-
teroposterior parallel opposing field treatment design and reported an increased risk of gas-troduodenal ulceration or bleeding. Severe hematologic toxicity associated with the use of high dose intra-arterial chemotherapeutic agents [39] and transient liver enzyme elevations 
were also reported. Kim et al. [36] reported that in most cases of liver enzyme elevation, the 
levels were less than five-fold the upper normal limit and the elevation was usually self-lim-
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ited. The incidence of high-grade (grade ≥3) liver toxicity was 5.7%. Anicteric ascites without elevation of alkaline phosphatase was also recorded. Hepatitis B virus reactivation after liver 
EBRT is also a well-described adverse event [11]; however, new-generation anti-viral agents effectively mitigate the condition. Discrimination of radiation-induced liver disease from the worsening of liver function associated with tumor progression or adverse effects of EBRT is 
sometimes challenging because of multiple comorbidities after treatment. Lethal conditions such as thrombus embolism after EBRT for treatment of HCC with IVC or atrial thrombi have 
been observed because of the high risk of dislodged thrombi [43].
Hypofractionated or Proton-Beam Radiation Therapy Techniques for Targeting 
PVTT
Modified fractional radiation schemes with delivery of a large fractional dose greater than the conventional 1.8–2 Gy fraction doses are referred to as hypofractionation. Although hypofractionated EBRT or stereotactic body radiotherapy (SBRT) for primary HCC target-ing has been broadly studied, the use of these regimens for PVTT treatment has rarely been 
reported [4, 38, 50]. Choi et al. [4] demonstrated the feasibility of SBRT for PVTT ablation. 
In their report, a median dose of 36 Gy (range, 30–39 Gy) given in three consecutive frac-tions was employed. The CR rate of PVTT was 11.1% and the median OS of patients with 
advanced HCC with PVTT was 12 months. No patient experienced grade 4 treatment toxic-ity. In their long-term follow-up study [38], additional patients were enrolled. Although not analyzed separately from the primary HCC, small tumor volumes of less than 32 cm3 signifi-
cantly correlated with better in-field tumor response rates and superior in-field progression-
Fig. 1. Computed tomography (CT) and magnetic resonance images (MRI) of a patient showing com-
plete response of PVTT to concurrent chemoradiation. A 70-year-old man was diagnosed with HCC with 
PVTT in the right main PV trunk and its subsegmental branches. He received definitive aimed concurrent 
chemoradiation of 45 Gy in 25 fractions with two cycles of intra-arterial 5-fluorouracil. Pretreatment 
α-fetoprotein and PIVKA-II levels of 22.6 ng/ml and 11097 ng/ml decreased to 10.8 and 111 ng/ml, re-spectively, 3 months after chemoradiation. A nearly complete PVTT response was evident in follow-up images at 3 months. (a, b) Pretreatment CT images, (c, d) pretreatment MRIs, and (e, f) CT images 3 months after completion of chemoradiation are shown. Arrows indicate PVTT.
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free survival (PFS). The in-field PFS rate at 1-year follow-up was 81.1% in tumor volumes <32 cm3 compared with 38.9% when volumes were ≥32 cm3. No patient experienced severe 
treatment-related toxicity after long-term follow-up. Wu et al. [50] combined TACE and a hy-
pofractionated schedule of EBRT with a 4–8 Gy fractional dose according to tumor volume. 
The objective response rate was 71.4% with a median OS of 11 months.Because of the close anatomical proximity to critical structures (e.g., the duodenum, other parts of the small bowel, large vessels) and continuous movement of liver parenchyma resulting from the respiratory motion or normal bowel movement, PVTT targeting by highly ablative SBRT doses requires highly precise IGRT techniques. Although highly focused tumor tracking targeting equipment has been developed, previous image-guided technical systems 
(e.g., the old-generation CyberKnife) usually required the implantation of gold fiducial mark-
ers to act as radiographic landmarks; the insertion of such markers required additional la-borious procedures with risks of procedure-related complications. Recently, immobilization 
vacuum body fixation devices combined with four-dimensional CT and various respiration regulatory techniques have been being used to reduce set-up errors and to increase target volume delineations [51, 52].Proton-beam therapy utilizes another type of radiation with a unique physical energy peak property, termed the Bragg peak. The characteristics of the Bragg peak permit excellent 
dose distribution and localization within a target area without significant increases in nor-mal tissue toxicity. Using this technique, promising treatment outcomes have been achieved 
in several types of cancer including HCC [22, 53, 54]. Sugahara et al. [55] studied proton-
beam RT in HCC with PVTT and obtained excellent results with a median local PFS of 21 months and median OS of 22 months. Of the 35 enrolled patients, 32 remained progression-free during a median follow-up of 21 months.
Unresolved Issues and Future Strategies of PVTT TreatmentMany former trials investigated the role of EBRT in PVTT management. However, sev-
eral issues have yet to be resolved in terms of more efficient PVTT control in the setting of HCC. Optimal dose-fraction schemes, appropriate target coverage, and proper combina-tion of systemic agents should be further examined. Despite continuing efforts to identify strong factors contributing to the treatment response, results are still unclear and ambigu-ous among studies. Because many study designs and enrolled cohorts are heterogeneous, 
it becomes difficult to interpret results consistently and uniformly. For example, the size or location of PVTT, underlying hepatic function, and the extent of primary HCC were differ-ent among studies, and proper analysis and comparison between studies required careful and judicious interpretation. In the modern therapeutic era, the best strategy is to achieve 
minimal toxicity and concomitantly to increase treatment efficacy. Because of the high prob-ability of intrahepatic and distant seeding in HCC associated with PVTT, highly effective local therapy combined with systemic agents may be reasonable therapeutic options in the future. We are currently awaiting results of a trial of administration of both sorafenib [28] [the only 
Food and Drug Administration (FDA)-approved targeted agent in advanced HCC] and high-dose, high-precision EBRT for PVTT treatment. Continuous development of radiotherapeu-tic, chemotherapeutic, and diagnostic imaging techniques may enhance therapeutic ratios and improve treatment outcomes in the future. 
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Conclusions
Looking at the results of previous studies, it is clear that there is not yet a definitive or optimized policy for management of PVTT while treatment modalities and techniques are continuously evolving. However, the use of EBRT is becoming more common because of the 
non-invasive nature of RT, recognition of high treatment efficacy, and rapid advances in RT technology. With regard to the radiotherapeutic aspect, delivering as much radiation as can be tolerated by surrounding normal tissue and combining radiation with other systemic thera-peutic modalities may be more reliable and associated with better treatment outcomes. More individualized approaches are necessary that take into account the location and size of the 
PVTT as well as the primary HCC status. If primary tumors are small (30–40 cm3) and are close to the PVTT, designing treatment to cover both targets with highly precise and high-dose RT techniques (e.g., image-guided SBRT) is preferable. However, in locally advanced large-vol-ume HCC with PVTT, a more protracted and conservative conventional fractionated 3D-CRT approach seems reasonable. In patients with good hepatic reserve and appropriate perfor-
mance status, more attempts at curative treatment including intensified chemo-radiotherapy should be performed if possible. Additionally, it is necessary to control subsequent intrahe-
patic disease dissemination and distant metastasis more efficaciously because those sites are major areas of treatment failure in the era of modern high-dose RT. In the next generation of 
treatment, we expect to see improved treatment outcomes of PVTT by more refined, state-of-the-art systems of modern EBRT techniques with the integration of novel systemic agents. We hope to be able to cure this devastating condition in the near future with improved under-
standing of the disease and more advanced and efficacious disease management strategies.
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